Project Grant R01HL174973
Award Date
9/1/24
Completion Date
5/31/29
Dollars Obligated
$563K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
West Hollywood, CA 90048, USA
Similar Awards
This Project Grant award for $684,814 was issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to investigate how tissue factors in the lung modulate the inflammatory response to viral infections, and how this process suppresses alveolar stem cells in emphysema, a subtype of chronic obstructive pulmonary disease (COPD). The research utilizes novel genetic tools, human organoid platforms,...
This $203,974 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a research project to investigate the effects of normal and diseased extracellular matrix (ECM) on the self-renewal and differentiation of airway basal epithelial cells. The project leverages novel tools developed by the co-PIs, including "inside-out" airway organoids and ECM hydrogels derived from normal and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,061,189 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Michigan to conduct research on immune crosstalk in lung injury and fibrosis. The research aims to study: 1) how epithelial cells regulate fibrosis and interact with myeloid cells, 2) mechanisms for impaired innate immunity against gram-positive infections in fibrosis, 3) delivery of cyclooxygenase inhibitors...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $248,955 to Howard University to support research on the roles of bivalent chromatin domains in regulating CD4+ T cell differentiation. The funding will enable the awardee to develop advanced single-cell epigenetic assays, such as the novel ISCCHIC-seq technique, to characterize chromatin structure and dynamics at bivalent domains...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $148,568.00 to Mayo Clinic to investigate the role of pleural mesothelial cells in lung injury, repair, and regeneration. The project will utilize lineage-tracing experiments in mouse models to study the function of these cells in the context of lung fibrosis and regeneration. The research aims to elucidate the signaling...
This federal Project Grant award for $690,626 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), to the Regents of the University of Michigan. The award funds research to study the role of type I interferon signaling in inhibiting the proliferation of alveolar type 2 (AT2) cells, which is critical for alveolar regeneration after acute lung injury. The research aims to identify the molecular mechanisms linking...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $602,955 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to National Jewish Health in Denver, Colorado. The 5-year grant, running from July 2024 to June 2029, will fund research to identify the unique functions and molecular drivers of airspace macrophage subsets during the resolution of lung inflammation and active lung repair. The primary objectives are to: 1) Test the hypothesis that a subset of airspace...
This federal Project Grant award for $605,678 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research into a novel mechanism regulating genome-wide mRNA expression in hypoxic lung disease. The research aims to explore the prospect that hypoxia activates a pathway operating in concert with hypoxia-inducible transcription factors (HIFs) to govern the hypoxic transcriptome. Specifically, the project will...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding research at Northwestern University to investigate the role of mitochondrial metabolism in alveolar epithelial cell differentiation and the development of lung fibrosis. The $616,000 award, effective September 1, 2024 through August 31, 2029, will support experiments using genetic mouse models to determine how mitochondrial...
This $651,019 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is funding research to elucidate the mechanisms behind dysfunctional epithelial repair processes that contribute to the development of pulmonary fibrosis. The research aims to identify factors driving aberrant epithelial cell states, determine the role of HIF signaling in preventing functional alveolar repair, and investigate niche-specific mechanisms regulating...